Ingalls & Snyder LLC’s ImmuCell ICCC Stock Holding History

Ingalls & Snyder LLC’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$60K	–	444
2020 Q4	$60K	Hold	10,000	–	–	﹤0.01%	419
2020 Q3	$54K	Hold	10,000	–	–	﹤0.01%	362
2020 Q2	$47K	Sell	10,000 -88,025	-90%	-$384K	﹤0.01%	395
2020 Q1	$372K	Buy	98,025 +1,780	+2%	+$8.76K	0.03%	295
2019 Q4	$496K	Buy	96,245 +2	+0%	+$10	0.03%	266
2019 Q3	$536K	Hold	96,243	–	–	0.03%	278
2019 Q2	$626K	Buy	96,243 +4,732	+5%	+$30K	0.03%	271
2019 Q1	$581K	Hold	91,511	–	–	0.03%	269
2018 Q4	$645K	Hold	91,511	–	–	0.03%	252
2018 Q3	$762K	Buy	+91,511	New	+$659K	0.03%	260

Other funds holding ICCC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMC

Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Ingalls & Snyder LLC's ICCC Position: Q1 2021 in Review

Ingalls & Snyder LLC sold out of ImmuCell (ICCC) in Q1 2021, closing a stake of 10,000 shares — an estimated $60K sold.

Ingalls & Snyder LLC first reported a position in ICCC in Q3 2018 and held it in 10 quarters. The position peaked at $762K in Q3 2018. 28 funds tracked by Wall St. Rank hold ICCC as of Q1 2021.

Ingalls & Snyder LLC reported no remaining ImmuCell position as of Q1 2021 after selling out during the quarter.
Ingalls & Snyder LLC sold 10,000 ImmuCell shares in Q1 2021, an estimated $60K.
Ingalls & Snyder LLC first reported a position in ImmuCell in Q3 2018 and held it in 10 quarters.
Ingalls & Snyder LLC's ImmuCell position peaked at $762K in Q3 2018.
28 funds tracked by Wall St. Rank held ImmuCell as of Q1 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2021, filed 21 Apr 2021.